Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00144677
- Locations
- 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States
Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 130
- Registration Number
- NCT00141037
- Locations
- 🇺🇸
UCLA - Department of Pediatrics, Division of Nephrology, Los Angeles, California, United States
🇺🇸Children's Hospital Boston - Division of Nephrology, Boston, Massachusetts, United States
🇺🇸Children's Hospital of New Orleans-Department of Pediatric Nephrology, New Orleans, Louisiana, United States
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00136903
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸St. Francis Hospital, Indianapolis, Indiana, United States
🇺🇸New York Medical College, Valhalla, New York, United States
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2015-10-06
- Target Recruit Count
- 210
- Registration Number
- NCT00134004
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States
🇺🇸Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 77
- Registration Number
- NCT00133887
- Locations
- 🇫🇷
Hôpital Edouard Herriot - Service de Dermatologie, Lyon, France
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00133367
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection
- Conditions
- Interventions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 85
- Registration Number
- NCT00133172
Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
- Conditions
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 20
- Registration Number
- NCT00125307
- Locations
- 🇭🇰
Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2012-04-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1
- Registration Number
- NCT00121186
- Locations
- 🇺🇸
Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States
🇺🇸Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States
🇺🇸Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States
Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 293
- Registration Number
- NCT00118742
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.